| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Steven Pipe | |
| P2860 | cites work | Pneumocystis carinii pneumonia among persons with hemophilia A | Q28274376 |
| Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. | Q33962399 | ||
| Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient | Q34339769 | ||
| Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study | Q34455485 | ||
| Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. | Q34555431 | ||
| Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia | Q34661163 | ||
| Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products | Q34683219 | ||
| The overall effectiveness of prophylaxis in severe haemophilia | Q35106860 | ||
| A global view on prophylaxis: possibilities and consequences | Q35112430 | ||
| Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia | Q36291059 | ||
| Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience | Q36381542 | ||
| Consideration in hemophilia therapy selection | Q36456680 | ||
| Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. | Q36536149 | ||
| Modern treatment of haemophilia | Q36794921 | ||
| An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products | Q37307945 | ||
| Assessing health-related quality-of-life in individuals with haemophilia | Q38498570 | ||
| Human immunodeficiency virus infection in the United States: a review of current knowledge | Q39600138 | ||
| Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). | Q40528993 | ||
| Transmission of West Nile Virus through Blood Transfusion in the United States in 2002 | Q40550030 | ||
| Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients | Q40654703 | ||
| Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation | Q43627159 | ||
| Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12- | Q43948995 | ||
| Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders | Q45858187 | ||
| The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. | Q45858196 | ||
| Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr | Q45864545 | ||
| Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. | Q45865894 | ||
| A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group | Q45872823 | ||
| Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males | Q45876072 | ||
| Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States | Q45876110 | ||
| Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. | Q45877719 | ||
| Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients | Q45877835 | ||
| Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. | Q45880382 | ||
| Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment | Q45887787 | ||
| Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators | Q45890265 | ||
| Medicine betrayed: hemophilia patients and HIV in the US. | Q50490290 | ||
| Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. | Q51037857 | ||
| Transfusion transmission of vCJD: a crisis avoided? | Q51633849 | ||
| Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. | Q53326531 | ||
| Removal of parvovirus B19 from hemoglobin solution by nanofiltration. | Q54035277 | ||
| Parvovirus B19 DNA contamination in coagulation factor VIII products. | Q54390828 | ||
| Recombinant clotting factors. | Q55049788 | ||
| Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products | Q71912358 | ||
| A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group | Q73305273 | ||
| Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group | Q74006014 | ||
| Prion diseases | Q76378391 | ||
| Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation | Q81449749 | ||
| Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients | Q81761505 | ||
| P921 | main subject | hemophilia | Q134003 |
| hemophilia A | Q2092064 | ||
| antihemophilic factor, human recombinant | Q4661156 | ||
| P304 | page(s) | 117-125 | |
| P577 | publication date | 2009-07-13 | |
| P1433 | published in | Biologics: Targets and Therapy | Q4915042 |
| P1476 | title | Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A | |
| P478 | volume | 3 |
| Q45863724 | Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A |
| Q35205428 | Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A |
| Q34111482 | Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII |
| Q58761664 | Practical aspects of extended half-life products for the treatment of haemophilia |
| Q27001016 | Switching treatments in haemophilia: is there a risk of inhibitor development? |
| Q38408739 | Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A |
Search more.